search icon
  • Print
  • ShareThis
  • Text Size

In order to contribute to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.


Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.

RSS Feed Print Category View
Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves
Posted: Monday, January 27, 2014 1:44 PM
Joined: 2/20/2013
Posts: 40

"Gilead Sciences' hepatitis C drug Sovaldi may mark a tipping point. Undoubtedly a breakthrough treatment, Sovaldi bears an undoubtedly high price tag: $84,000 for 12 weeks of treatment. And payers, seeing the number of high-priced therapies now on the market, with more in the pipeline, are balking.


As Bloomberg reports, the Sovaldi launch has pharmacy benefits managers casting about for new tactics to control drug spending--and those new tactics could sap the power from some long-standing pharma strategies.


PBMs might refuse to pay a higher price for drugs that are more convenient to take than cheaper alternatives are. They might not cover all new drugs in a new generation of treatments, opting to analyze the field and choose the best--and most cost-effective--option. They might even bring in outside experts to review the data, just as cost-effectiveness watchdogs in other countries do."

Read more: Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves - FiercePharma


| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site